| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e62e9eac468ee394ad880c2e2a0f670 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2202-064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M16-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02 |
| filingDate |
2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de0bc8683fcf791ee8d126088c74b4b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8924de94972bddf7ed0e5a3e2f44a7c |
| publicationDate |
2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107530357-A |
| titleOfInvention |
Dry powder inhaler containing fluticasone propionate and salmeterol xinafoate |
| abstract |
The present invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein the delivered dose of fluticasone propionate is less than 100 μg per actuation; The dose provided a baseline-adjusted FEV 1 of more than 150 mL in patients within 30 minutes. A method of treating a patient comprising administering to the patient a dry powder drug having fluticasone propionate, salmeterol xinafoate, and a lactose carrier; wherein the delivered dose of fluticasone propionate is less than 100 pg per actuation; The above doses provided a baseline-adjusted FEV 1 of more than 150 mL in patients within 30 minutes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110064110-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110201278-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110201280-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110201281-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110201280-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110201281-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110201278-B |
| priorityDate |
2015-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |